BACKGROUND/AIMS: Commercially available @entity4023 solutions are usually too thick to inject through catheters and need dilution with normal saline (NS) before use, which increases the risk of contamination. We evaluated the usefulness of ready-to-use 0.4% @entity4023 , Endo-Ease (EE; UNIMED Pharm. Inc., Seoul, Korea). METHODS: We performed a prospective multicenter randomized study from May 2011 to September 2012. @entity1 requiring endoscopic resection (ER) for @entity14 at two referral hospitals were enrolled. RESULTS: One hundred fifty-four @entity1 (72 with a @entity356 and 82 with a @entity14 ) were included in intention-to-treat analysis. Thirty-seven @entity356 and 43 @entity14 were enrolled in the EE group. The usefulness rate was significantly higher in the EE group than in the NS group (89.2% vs. 60.0% for @entity356 and 95.3% vs. 67.7% for @entity14 , p<0.001). In the EE group, the ease of mucosal resection was significantly higher than in the NS group (p<0.001). The injected volume was smaller in the EE group than in the NS group (p<0.05). CONCLUSIONS: The use of EE reduced the need for additional injections and improved the ease of ER. A submucosal injection of EE is useful for the ER of both @entity14 .

Usefulness of Ready-to-Use 0.4% XXXX (Endo-Ease) in the Endoscopic Resection of Gastrointestinal Neoplasms.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric neoplasm', 'gastric neoplasms'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal neoplasm', 'gastric or colorectal neoplasm', 'colorectal neoplasms', 'gastric and colorectal neoplasms'] @entity4023 :: ('MESH:D006820', 'Chemical') :: ['sodium hyaluronate']
@entity4023 :: (MESH:D006820,Chemical) :: ['Sodium Hyaluronate']
